Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.
Shenzhen Chipscreen Biosciences Co. Ltd. has divulged histone deacetylase (HDAC) inhibitors found to be potentially useful for the treatment of cancer.
Shanghai Curegene Pharmaceutical Co. Ltd. has identified thyroid hormone receptor β (THR-β) agonists that are potentially useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), diabetes and obesity.
Scientists from the Purdue Research Foundation have prepared and tested prostate-specific membrane antigen (PSMA)-targeting ligands covalently linked to the poly(ADP-ribose) polymerase (PARP) inhibitor niraparib through a releasable, reductively cleavable NADS linker.
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor agonists reported to be potentially useful for the treatment of mood disorders.
Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer.
Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors reported to be potentially useful for the treatment of cancer.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has divulged tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 inhibitors that are potentially useful for the treatment of cancer.
RSS
